Cited by 852Glioma Diagnosis and TreatmentCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Dissecting the genomic complexity underlying medulloblastoma

Open access
Jones, David T. W., Jäger, Natalie, Kool, Marcel, Zichner, Thomas, Hutter, Barbara, Sultan, Marc, Cho, Yoon-Jae, Pugh, Trevor J. +82 more·2012·Nature

Abstract

Medulloblastoma is the most common brain tumour in children; using whole-genome sequencing of tumour samples the authors show that the clinically challenging Group 3 and 4 tumours can be tetraploid, and reveal the expression of the first medulloblastoma fusion genes identified. Medulloblastoma is the most common malignant brain tumour in children. Four papers published in the 2 August 2012 issue of Nature use whole-genome and other sequencing techniques to produce a detailed picture of the genetics and genomics of this condition. Notable findings include the identification of recurrent mutations in genes not previously implicated in medulloblastoma, with significant genetic differences associated with the four biologically distinct subgroups and clinical outcomes in each. Potential avenues for therapy are suggested by the identification of targetable somatic copy-number alterations, including recurrent events targeting TGFβ signalling in Group 3, and NF-κB signalling in Group 4 medulloblastomas. Medulloblastoma is an aggressively growing tumour, arising in the cerebellum or medulla/brain stem. It is the most common malignant brain tumour in children, and shows tremendous biological and clinical heterogeneity1. Despite recent treatment advances, approximately 40% of children experience tumour recurrence, and 30% will die from their disease. Those who survive often have a significantly reduced quality of life. Four tumour subgroups with distinct clinical, biological and genetic profiles are currently identified2,3. WNT tumours, showing activated wingless pathway signalling, carry a favourable prognosis under current treatment regimens4. SHH tumours show hedgehog pathway activation, and have an intermediate prognosis2. Group 3 and 4 tumours are molecularly less well characterized, and also present the greatest clinical challenges2,3,5. The full repertoire of genetic events driving this distinction, however, remains unclear. Here we describe an integrative deep-sequencing analysis of 125 tumour–normal pairs, conducted as part of the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. Tetraploidy was identified as a frequent early event in Group 3 and 4 tumours, and a positive correlation between patient age and mutation rate was observed. Several recurrent mutations were identified, both in known medulloblastoma-related genes (CTNNB1, PTCH1, MLL2, SMARCA4) and in genes not previously linked to this tumour (DDX3X, CTDNEP1, KDM6A, TBR1), often in subgroup-specific patterns. RNA sequencing confirmed these alterations, and revealed the expression of what are, to our knowledge, the first medulloblastoma fusion genes identified. Chromatin modifiers were frequently altered across all subgroups. These findings enhance our understanding of the genomic complexity and heterogeneity underlying medulloblastoma, and provide several potential targets for new therapeutics, especially for Group 3 and 4 patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature11284

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Jones, D. T. W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, V., Stütz, A. M., Rausch, T., Warnatz, H.-J., Ryzhova, M., Bender, S., Sturm, D., Pleier, S., Cin, H., Pfaff, E., Sieber, L., Wittmann, A., Remke, M., Witt, H., Hutter, S., Tzaridis, T., Weischenfeldt, J., Raeder, B., Avci, M., Amstislavskiy, V., Zapatka, M., Weber, U. D., Wang, Q., Lasitschka, B., Bartholomae, C. C., Schmidt, M., von Kalle, C., Ast, V., Lawerenz, C., Eils, J., Kabbe, R., Benes, V., van Sluis, P., Koster, J., Volckmann, R., Shih, D., Betts, M. J., Russell, R. B., Coco, S., Paolo Tonini, G., Schüller, U., Hans, V., Graf, N., Kim, Y.-J., Monoranu, C., Roggendorf, W., Unterberg, A., Herold-Mende, C., Milde, T., Kulozik, A. E., von Deimling, A., Witt, O., Maass, E., Rössler, J., Ebinger, M., Schuhmann, M. U., Frühwald, M. C., Hasselblatt, M., Jabado, N., Rutkowski, S., von Bueren, A. O., Williamson, D., Clifford, S. C., McCabe, M. G., Peter Collins, V., Wolf, S., Wiemann, S., Lehrach, H., Brors, B., Scheurlen, W., Felsberg, J., Reifenberger, G., Northcott, P. A., Taylor, M. D., Meyerson, M., Pomeroy, S. L., Yaspo, M.-L., Korbel, J. O., Korshunov, A., Eils, R., Pfister, S. M., & Lichter, P.
Affiliations
  • German Cancer Research Center (DE)
  • European Molecular Biology Laboratory (DE)
  • Max Planck Institute for Molecular Genetics (DE)
  • Stanford University (US)
  • Broad Institute (US)
  • Burdenko Neurosurgery Institute (RU)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Hospital for Sick Children (CA)
  • Heidelberg University (DE)
  • Ospedale Policlinico San Martino (IT)
  • Institut für Neuropathologie (DE)
  • Evangelisches Krankenhaus Bielefeld (DE)
  • Universitätsklinikum des Saarlandes (DE)
  • University of Würzburg (DE)
  • University Hospital Heidelberg (DE)
  • Olgahospital (DE)
  • University Medical Center Freiburg (DE)
  • University Children's Hospital Tübingen (DE)
  • University Hospital Münster (DE)
  • McGill University Health Centre (CA)
  • University Medical Center Hamburg-Eppendorf (DE)
  • Royal Victoria Infirmary (GB)
  • University of Cambridge (GB)
  • Cnopf´sche Kinderklinik (DE)
  • Heinrich Heine University Düsseldorf (DE)
Corresponding author
  • Eils, Roland
  • Pfister, Stefan M.
  • Lichter, Peter
Venue
Nature
Published
2012-07-25
Volume
488
Issue
7409
Pages
100-105
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2167532631
Cited by
839
References
27
Citations by year
2026: 8 · 2025: 31 · 2024: 28 · 2023: 41 · 2022: 42 · 2021: 60 · 2020: 51 · 2019: 49 · 2018: 69 · 2017: 73 · 2016: 86 · 2015: 81 · 2014: 89 · 2013: 102 · 2012: 28
FWCI
45.68
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
  • OPUS (Augsburg University) (submittedVersion, cc-by-nc-sa)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • Pediatric Brain Tumor Foundation
  • Deutsches Krebsforschungszentrum
  • Children's Cancer and Leukaemia Group
  • Cancer Research UK (13457)
  • Brain Tumour Charity (16/92, 10/106)
  • Bundesministerium für Bildung und Forschung (01GS0883)
  • Hungarian Scientific Research Fund
  • Max-Planck-Gesellschaft
  • Deutsche Krebshilfe (109252)
  • Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
  • National Cancer Institute (R01CA109467)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD018655)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
medulloblastoma, Group 3 medulloblastoma, Group 4 medulloblastoma, tetraploidy, somatic copy number alterations, TGF-beta signaling, NF-κB signaling, recurrent mutations, pediatric brain tumors, tumor heterogeneity
MeSH terms
Patched Receptors, Patched-1 Receptor, Aging, Amino Acid Sequence, Cell Transformation, Neoplastic, Cerebellar Neoplasms, Child, Chromatin, Chromosomes, Human, DNA Helicases, DNA-Binding Proteins, Humans, Medulloblastoma, Methylation, Mutation, Neoplasm Proteins, Nuclear Proteins, Phosphoprotein Phosphatases, Polyploidy, Receptors, Cell Surface, Transcription Factors, Signal Transduction, Oncogene Proteins, Fusion, Genome, Human, Sequence Analysis, RNA, T-Box Domain Proteins, Genomics, Wnt Proteins, beta Catenin, DEAD-box RNA Helicases, Hedgehog Proteins, Histone Demethylases, High-Throughput Nucleotide Sequencing, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review